ARPA-H funds five teams to make RNA medicines on demand

ARPA-H announced on 1 September 2026 that it has selected five teams for its GIVE program, Genetic Medicines and Individualized Manufacturing for Everyone, with awards of up to $125 million in total. The recipients are Centillion Biosciences, HDT Bio Corp., Massachusetts General Hospital, Waterfall Scientific and the University of Utah.

The program targets manufacturing rather than biology. Its stated goal is an automated network capable of producing individualized RNA-based genetic medicines on demand, replacing centralized production with distributed capacity that can make a treatment locally, near the patient who needs it. ARPA-H frames the intended effects as lower cost, shorter production timelines and wider access for patients with cancer, rare genetic conditions and chronic disease.

The bottleneck this addresses is real and specific. A therapy designed for one person cannot amortize a centralized plant across a large batch, which is why bespoke genetic medicines have so far reached individual patients through one-off academic heroics rather than through a supply chain. Whether an automated distributed network can be built to a regulator’s satisfaction is the open question, and none of the five teams has demonstrated one yet. This is an award, at the start of the work.